Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18549966 | 0.98 | CYP2A6 (0.46) | CYP2A6LMNATSHRNPC1RAB9A | |
| SCHEMBL2543007 | 0.95 | CYP2A6 (0.48) | CYP2A6LMNATSHRNPC1RAB9A | |
| SCHEMBL695559 | 0.90 | CYP2A6 (0.52) | CYP2A6LMNATSHRNPC1RAB9A | |
| SCHEMBL6570335 | 0.80 | CYP2A6 (0.48) | CYP2A6LMNATSHRNPC1RAB9A | |
| SCHEMBL11307092 | 0.78 | CNR2 (0.42) | TSHRALDH1A1MAPTMAPK1POLB | |
| SCHEMBL6075548 | 0.76 | CYP2A6 (0.40) | CYP2A6LMNATSHRNPC1RAB9A | |
| SCHEMBL3807297 | 0.75 | NOTUM (0.42) | CYP2A6TSHRMAPTMAPK1IDO1 | |
| SCHEMBL29802156 | 0.74 | CYP2A6 (0.67) | CYP2A6LMNATSHRNPC1RAB9A | |
| SCHEMBL671133 | 0.74 | CYP2A6 (0.67) | CYP2A6LMNATSHRNPC1RAB9A | |
| SCHEMBL29883244 | 0.74 | CYP2A6 (0.67) | CYP2A6LMNATSHRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111051325-B | Spirothiocyclobutane nucleosides | 詹森药业有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-4148048-A1 | LONG-ACTING LOW-ADDICTION HNK DERIVATIVE AND PREPARATION METHOD THEREFOR | Shenzen Ruijian Biotechnology Co., Ltd. (CN) | 2023-03-15 | — | — | EP | disclosed |
| EP-3676276-B1 | SPIROTHIETANE NUCLEOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-08 | — | — | EP | disclosed |
| US-20210139524-A1 | SPIROTHIETANE NUCLEOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
| WO-2021078132-A1 | INHIBITORS OF MTOR-MEDIATED INDUCTION OF AUTOPHAGY | SIRONAX LTD (GB) | 2021-04-29 | — | — | WO | disclosed |
| EP-3676276-A1 | SPIROTHIETANE NUCLEOSIDES | Janssen Pharmaceutica NV (BE) | 2020-07-08 | — | — | EP | disclosed |
| CN-111051325-A | Spirothiacyclobutanenucleosides | 詹森药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| WO-2019043177-A1 | SPIROTHIETANE NUCLEOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-07 | — | — | WO | disclosed |
| US-20170056313-A1 | NAIL COATINGS HAVING ENHANCED ADHESION | CREATIVE NAIL DESIGN, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| EP-1064262-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS CYCLIC GMP MODULATORS IN MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999042444-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS CYCLIC GMP MODULATORS IN MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139524-A1 | SPIROTHIETANE NUCLEOSIDES | SAMHD1, SLC28A1, SLC28A2 | CYP2A6 316/4885LMNA 321/4885TSHR 4528/4885 |
| US-20170056313-A1 | NAIL COATINGS HAVING ENHANCED ADHESION | POLR1C, PIK3C3, NACA | CYP2A6 2233/4885LMNA 1692/4885TSHR 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.